Telithromycin (Ketek) – Part 2
Telithromycin was approved for use by the FDA in April, 2004 for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae. Other uses approved were for the treatment of acute bacterial exaceration of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis and acute bacterial sinusitis by the three previous organisms, as well as with Staphylococcus aureus.
In addition, It is widely used by chronic Lyme patients in an off-label use for supposed pulmonary infection with Mycoplasma.
Copyright 2006 Insidesurgery.com